In China, a study with a larger sample size reported that 89 r/r PTCL patients treated with geptanolimab, an anti-PD-1 antibody, had ORR and CR rates of 40.4% and 14.6%, respectively (12). Here, PDCD1 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.